Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer  by Sasaki, Hidefumi et al.
ORIGINAL ARTICLE
Evaluation of Kras Gene Mutation and Copy Number Gain
in Non-small Cell Lung Cancer
Hidefumi Sasaki, MD, PhD, Yu Hikosaka, MD, PhD, Osamu Kawano, MD, PhD,
Satoru Moriyama, MD, PhD, Motoki Yano, MD, PhD, and Yoshitaka Fujii, MD, PhD
Introduction: Recent studies for the characterization of the lung
cancer genome have suggested that Kras gene was frequently
amplified and correlated with activating mutations of Kras, which
occur in approximately 5 to 10% of Japanese lung cancers.
Methods: We analyzed Kras mutation and Kras copy number in
172 Japanese non-small cell lung cancer (NSCLC) cases and their
relation to the survival of patients. We also studied using fluores-
cence in situ hybridization to provide direct evidence of Kras
amplification in 40 clinical specimens.
Results: In 172 NSCLC cases, increased Kras copy number existed
in 19 (11.0%) cases. Increased Kras gene copy number was corre-
lated with Kras mutation. Nevertheless, Kras gene copy number
gain was not correlated with gender, pathological subtypes, stages,
and smoking status. Increased Kras copy number was not associated
with overall survival in these 172 cases; however, patients with
increased Kras copy number and Kras mutant had significantly
worse prognosis, when compared with patients with Kras wild type
and Kras not increased. From the fluorescence in situ hybridization
analysis, Kras polysomy or amplified patients showed significantly
worse prognosis, when compared with Kras disomy patients.
Conclusion: Kras mutation plus increased copy number was a
predictor of poor clinical outcome in patients with NSCLC.
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(J Thorac Oncol. 2011;6: 15–20)
Lung cancer is the deadliest cancer in many developedcountries. Mutations of Kras gene occur in approximately
5 to 10% of Japanese non-small cell lung cancers
(NSCLCs),1–3 and these mutations are associated with a
distinct clinicopathologic subset of NSCLC marked by a
strong association with smokers, patients with adenocarcino-
mas, poor prognosis, ethnics, and in resistance to treatment
with tyrosine kinase inhibitors.4 On the other hand, early
studies in cell lines and murine models established the pos-
sibility that amplification of wild-type Ras genes could lead
to malignant transformation.5,6 Recent studies using low-
resolution, conventional comparative genome hybridization
have identified frequent copy number gains of the 12p12. 1
region, including Kras from several cancers.7–11 Moreover, in
recent large-scale systematic assessments of the lung adeno-
carcinoma genome, analysis of single-nucleotide polymor-
phism arrays has identified Kras copy number gains as one of
the most common focal amplification events in adenocarci-
noma of the lung.12,13
Previous report using fluorescence in situ hybridization
(FISH) detected Kras amplification in 7 of 100 white
NSCLC.14 Another report investigated Kras copy number
using quantitative real-time polymerase chain reaction
(qPCR) in several cancers.15 Nevertheless, Kras copy number
status at Japanese population using FISH has not been well
reported. Because we previously reported the epidermal
growth factor receptor (EGFR) copy number gains in NSCLC
using FISH16,17 and qPCR techniques,18 we also evaluated to
determine the Kras gene mutation status, and Kras gene
amplification may bring important information for the surgi-
cally treated Japanese patients with NSCLC. The findings
were compared with the clinicopathologic features of NSCLC
in this study. FISH analysis was also performed.
PATIENTS AND METHODS
Patients
NSCLC tissues were obtained by surgical excision
from 172 patients with NSCLC at Nagoya City University
Hospital. EGFR mutation19–22 and Kras mutations3 were
already analyzed and reported. The patients were biased
population, as mutation centric. The research was approved
by the Institutional Review Board of the hospital. All the
patients consented to the use of their tissues for the present
analysis. The tissues were placed in liquid nitrogen immedi-
ately after resection (macrodissected) or fixed by formalin
and paraffin embedded. Genomic DNA was extracted using
Wizard SV Genomic DNA Purification System (Promega)
according to the manufacturer’s instructions. Within the pa-
tients, we have also analyzed the Kras amplified status for 40
NSCLC cases using FISH methods.
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Analysis of Kras Copy Number
Kras copy number was analyzed for 172 patients with
NSCLC by qPCR, performed on 7500 Real-Time PCR Sys-
tem (Applied Biosystems) by using a QuantiTect SYBR
Green kit (Qiagen, Inc., Valencia, CA).14,18 The run per each
patient was triplicate. We quantified each tumor DNA by
comparing the target locus to the reference line 1, a repetitive
element for which copy number per haploid genome is
similar among all the human normal and neoplastic cells.
Quantification is based on standard curves from a serial
dilution of human normal genomic DNA. The relative Kras
copy number was also normalized to the normal human
genomic DNA as a calibrator. Copy number change of Kras
gene relative to the line 1 and the calibrator was determined
by using the formula (TKras/Tline 1)/(CKras/Cline 1), where
TKras and Tline 1 are quantities from tumor DNA by using
Kras and line 1, and CKras and Cline 1 are quantities from
calibrator by using Kras and line 1. Conditions for qPCR
reaction were as follows: one cycle of 50°C for 2 minutes;
one cycle of 95°C for 15 minutes; 40 cycles of 95°C for 15
seconds; 56°C for 30 seconds; and 72°C for 34 seconds. At
the end of the PCR reaction, samples were subjected to a
melting analysis to confirm specificity of the amplicon.
Kras primers were 5GGCCTGCTGAAAATGACT-3 and
5GAATGGTCCTGCACCAGTA-3 and they amplified. To-
tal DNA content was estimated by assaying line 1 elements
for each sample using the primers 5-AAAGCCGCTCAAC-
TACATGG-3 and 5-TGCTTTGAATGCGTCCCAGAG-
3. Kras increased copy number (ICN) was determined as
positive when the copy number was more than 3, according to
the Takano et al.23 and Okuda et al.24 criteria.
FISH Analysis
Tumor specimens were obtained at surgical operation
and embedded in paraffin. Serial sections (6 mm) containing
representative malignant cell were stained with hematoxylin
and eosin. Gene copy number per cell was investigated by
FISH using the GPS KRAS (TexRed)/CEN12q(FITC) Dual
Color FISH probe (GPS laboratories, Kawasaki, Japan) ac-
cording to a published protocol.25 Sections were incubated at
56°C overnight, deparaffinized, and dehydrated. After incu-
bation in 2 saline sodium citrate buffer (2SSC; pH, 7.0)
at 75°C for 15 to 25 minutes, sections were digested with
protein K (0.25 mg/ml in 2SSC; pH, 7.0) at 37°C for 15 to
25 minutes, rinsed in 2SSC at room temperature for 5
minutes, and dehydrated using ethanol in a series of increas-
ing concentrations. The KRAS/CEN 12q probe set was ap-
plied per the manufacturer’s instructions onto the selected
area based on the presence of tumor foci on each slide. The
slides were incubated at 80°C for 8 to 10 minutes for
codenaturation of chromosomal and probe DNA and then
placed in a humidified chamber at 37°C for 20 to 24 hours to
allow hybridization to occur. Posthybridization washes were
performed in 1.5 M urea and 0.1SSC at 45°C for 30
minutes and in 2SSC for 2 minutes at room temperature.
Pathologist who was blinded to the patients’ clinical charac-
teristics and all other molecular variables performed FISH
analysis independently. Patients were classified according to
the criteria by Cappuzzo et al.26 with ascending number of
copies of the Kras gene per cell and the frequency of tumor
cells with specific number of copies of the Kras gene and
chromosome 12q centromere: gene amplification (defined by
presence of tight Kras gene clusters and a ratio of Kras gene
to chromosome of 2 or 15 copies of Kras per cell in
10% of analyzed cells), high polysomy (4 copies in
40% of cells), and low polysomy (4 copies in 10–40% of
cells) were considered as ICN in our analysis. Disomy (2
copies in 90% of cells), low trisomy (2 copies in 40%
of cells, three copies in 10–40% of cells, and 4 copies in
10% of cells), and high trisomy (2 copies in 40% of
cells, three copies in 40% of cells, and 4 copies in 10%
of cells) were considered as normal copy number.
Statistical Analysis
For comparisons of proportions, Fisher’s exact test was
used. The overall survival was examined by the Kaplan-
Meier methods, and differences were examined by the log-
rank test. Association of risk factors associated with survival
was evaluated using Cox proportional hazards regression
model. Only those variables with significant results in uni-
variate analysis were included in the multivariate analysis.
All analysis was done using a Stat View (version 5, SAS
Institute Inc., Cary, NC) software and was considered signif-
icant when the p value was less than 0.05.
RESULTS
Kras Mutation Status in 172 Patients
In the previous report, we detected 11% of Kras mu-
tation in our lung cancer cohort.3 From the same genotyping
assay using the LightCycler, 36 cases were detected to have
a Kras mutation in this cohort. We have mainly focused on
Kras mutant patients for further copy number and FISH
analyses, and this Kras mutation rate did not reflect actual
mutation rate. Kras mutation was found in 25 of 106 (23.6%)
males and 11 of 66 (16.7%) females; 10 of 67 (14.9%)
patients who were aged 64 years and younger and 26 of 105
(24.8%) patients who were older than 65 years; 34 of 137
(24.8%) adenocarcinoma and 2 of 35 (5.7%) nonadenocarci-
noma; 11 of 68 (16.2%) never smokers and 25 of 104 (24.0%)
smokers; and 15 of 96 (15.6%) of stage I and 21 of 76
(13.2%) of stages II to IV NSCLC. Adenocarinoma showed
significantly higher Kras mutation rate. Advanced stage
trends shown higher Kras mutation rate.
Kras Copy Number in 172 Patients with Lung
Cancer
Kras copy numbers of 172 samples from patients with
lung cancer were analyzed by qPCR. Nineteen of 172 cases
were found to have increased Kras copy number (3.0).
Only two cases had more than four Kras copy number.
Relationship between Kras copy number and clinical-patho-
logic factors in patients with lung cancer was shown in Table
1. Increased Kras copy number was found in 11 of 106
(10.4%) males and 8 of 66 (12.1%) females; 5 of 75 (6.7%)
of patients who were aged 65 years and younger and 14 of 97
(14.4%) of those who were older than 65 years; 13 of 137
(9.5%) of adenocarcinoma and 7 of 36 (19.4%) of nonade-
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nocarcinoma; and 6 of 68 (8.9%) never smokers and 13 of
104 (12.5%) ever smokers. Kras copy number was not
significantly correlated with any of the clinical-pathologic
factors. In the 36 cases with Kras mutation in this cohort,
eight cases had increased Kras copy number. Kras copy
number was more frequently increased within Kras mutant
type patients (p  0.0312). In the 46 cases with EGFR
mutation in this cohort, only one case had increased Kras
copy number. Kras copy number was more frequently in-
creased within EGFR wild-type patients (p  0.0216).
FISH Analyses in 40 Patients with Lung Cancer
We identified only one case of amplification of Kras
from 40 cases using FISH analysis. We also detected one
high-polysomy case (Figure 1). Using the criteria by Cap-
puzzo et al., two cases were FISH positive. We have also
detected six low-polysomy cases. In this cohort, these eight
were evaluated as ICN cases. ICN patients were 5 of 26
(19.2%) males and 3 of 14 (21.4%) females; 2 of 17 (11.8%)
patients who were aged 65 years and younger and 6 of 23
(26.1%) of those who were older than 65 years; 5 of 37
(13.5%) of adenocarcinoma and 3 of 3 (100%) of nonadeno-
carcinoma; 1 of 10 (10.0%) never smokers and 7 of 30
(23.3%) of ever smokers; and 2 of 17 (11.8%) of stage I and
6 of 23 (26.1%) of stages II to IV. Again, we have mainly
focused on Kras mutant patients for FISH analyses (mutation
centric), and there was no significant correlation between the
Kras ICN and these clinical-pathologic factors, except for
pathological bias (Table 2). Thirty-nine patients were exam-
ined both by PCR and FISH. The average Kras copy number
of eight ICN patients (2.664  1.145) was significantly
higher than that of 31 patients (1.872  0.845) (p  0.0357,
Student’s t test) (p  0.0164, Spearman’s rank correlation).









Mean age (yr) 69.7  6.7 65.0  9.7 0.0397
Stage
I 10 (9.6%) 86 (90.4%) 0.8099
II–IV 9 (11.8%) 67 (88.2%)
Lymph node metastasis
N0 13 (10.9%) 106 (99.1%) 0.9999
N 6 (11.3%) 47 (88.7%)
Smoking
Never smoker 6 (8.8%) 62 (91.2%) 0.6199
Smoker 13 (12.5%) 91 (87.5%)
Kras mutation
Wild 11 (8.1%) 125 (91.9%) 0.0312
Mutation 8 (22.2%) 28 (77.8%)
EGFR mutation
Wild 18 (14.3%) 108 (85.7%) 0.0216
Mutation 1 (2.2%) 45 (97.8%)
Pathological subtype
Adeno 13 (9.5%) 124 (90.5%) 0.2270
Nonadeno 6 (17.1%) 29 (82.9%)
Age (yr)
65 5 (6.7%) 70 (93.3%) 0.1420
65 14 (14.4%) 83 (85.6%)
Gender
Male 11 (10.4%) 95 (89.6%) 0.8040
Female 8 (12.1%) 58 (87.9%)
N, lymph node metastasis positive; adeno, adenocarcinoma.
FIGURE 1. Fluorescence in situ hy-
bridization (FISH) analysis for lung
cancer tissues. Left upper, disomy
case; right upper, low polysomy case;
left lower, high polysomy case; right
lower, amplification case.
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Relationships among Kras Mutation, Increased
Kras Copy Number, and Clinical Outcome
Within 172 patients, Kras mutant patients (15/36
were dead, median survival  41.3 months) had worse
prognosis than Kras wild-type patients (38/136 were dead,
median survival  77.3 months, p  0.0256). Then, we
classified into three groups: N (Kras normal copy number
and wild type), M or A (Kras mutation or Kras copy
number 3), and MA (Kras mutation and Kras copy
number 3). The Kaplan-Meier curves are shown in Fig-
ure 2. N patients showed best prognosis, M or A patients
showed intermediate prognosis, and MA patients showed
worst prognosis. Patients with Kras mutation and copy
number more than 3 had a statistically significantly worse
prognosis compared with those with wild-type Kras and
normal copy number (log-rank p  0.0294).
Kras ICN Status in the FISH Analysis in 40
Patients with NCSLC and Clinical Outcome
Within 40 patients, Kras ICN patients (6/8 were dead,
median survival  15.7 months) had worse prognosis than
Kras normal copy number patients (9/32 were dead, median
survival  41.3 months, p  0.062) (Figure 3). Although
clinical background was imbalanced in this cohort, multivar-
iate analysis also showed that FISH status (ICN) (hazard
ratio 3.092, 1.034–9.247, p 0.0434) but not pathological
stage (p  0.4319) was an independent prognostic factor.
DISCUSSION
In our study, Kras mutation, but not Kras copy number
itself, correlated with survival of patients with lung cancer.
Nevertheless, Kras mutation plus increased Kras copy num-
ber correlated with poor prognosis. In addition, from our
FISH analysis, Kras polysomy or amplified patients showed









Mean age (yr) 65.8  8.2 72.6  8.3 0.0602
Stage
I 2 (11.8%) 15 (88.2%) 0.4284
II–IV 6 (26.1%) 17 (73.9%)
Lymph node metastasis
N0 5 (62.5%) 20 (62.5%) 0.9999
N 3 (37.5%) 12 (37.5%)
Smoking
Never smoker 1 (10.0%) 9 (90.0%) 0.6526
Smoker 7 (23.3%) 23 (76.7%)
Kras mutation
Wild 2 (15.4%) 11 (84.6%) 0.9999
Mutation 6 (22.2%) 21 (77.8%)
EGFR mutation
Wild 8 (21.1%) 30 (78.9%) 0.9999
Mutation 0 (0.0%) 2 (100%)
Pathological subtype
Adeno 5 (13.5%) 32 (86.5%) 0.0057
Nonadeno 3 (100%) 0 (0.0%)
Age (yr)
65 2 (11.8%) 15 (88.2%) 0.1420
65 6 (26.1%) 17 (73.9%)
Gender
Male 5 (19.2%) 21 (80.8%) 0.9999
Female 3 (21.4%) 11 (78.6%)
Adeno, adenocarcinoma.
FIGURE 2. Kaplan-Meier curves of overall survival accord-
ing to Kras mutation and copy number in 172 patients. N
patients (Kras copy number  3 and Kras wild type) showed
best prognosis, M (Kras mutation) or A (Kras increased copy
number  3) patients showed intermediate prognosis, and
MA patients showed worst prognosis. Patients with Kras mu-
tation and copy number  3 had a statistically significantly
worse prognosis compared with those with wild-type Kras
and normal copy number (log-rank p  0.0294).
FIGURE 3. Kaplan-Meier curves of overall survival accord-
ing to Kras copy number in 40 patients according to the flu-
orescence in situ hybridization (FISH) status. Within 40 pa-
tients, Kras increased copy number (ICN) patients (6/8 were
dead, median survival  15.7 months) had worse prognosis
than Kras normal copy number patients (9/32 were dead,
median survival  41.3 months, p  0.062).
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poor prognosis. Thus, Kras copy number gain somehow plays
an important role in tumor progression of lung cancers.
Oncogene activation is one of the key processes under-
lying the development of cancer. Oncogenes can be activated
by a variety of mechanisms, such as overexpression and
protein mutation leading to elevated or altered activity. Ras
genes (including Kras and Nras) encode founding members
of an extensive family of small guanosine triphosphate
(GTP)ases, which regulates a variety of key cellular pro-
cesses through their function as molecular switches.27,28
Wild-type Ras proteins cycle between guanosine diphosphate
(GDP)- and GTP-bound forms, regulated by GTPase-activat-
ing protein, which activate their intrinsic catalytic activity
and by guanine nucleotide exchange factors, which stimulate
the exchange of GDP for GTP. In their GTP-bound forms,
these proteins engage a variety of effectors, such as RAF and
phoshoinositide 3-kinase, which mediate both normal and
oncogenic signaling effects. Common Ras-activating muta-
tions are located at codons 12 and 13, rendering the proteins
insensitive to the action of GTPase-activating proteins and
leading to constitutively GTP-bound, actively signaling forms.
Ras genes have also been found to undergo copy gains at low
frequencies in several cancer types.5,6,8,12,29,30 A recent high-
resolution study of copy number alterations in NSCLC revealed
recurrent copy number gains centered on the Kras locus, pro-
viding evidence that these gains are functionally significant
and under positive selection.12 Although Ras proteins mediate
a variety of oncogenic stimuli (including proliferative, sur-
vival, and antiapoptotic signals), they also have context-
dependent activities that can oppose the requirements for
tumor growth. In particular, the activity of oncogenic mutant
Ras can induce growth arrest or apoptosis, for example, in
primary cells,31,32 and wild-type Ras has been shown to act
similar to a tumor suppressor in some models.31 These
diverse, context-dependent activities make Ras proteins a
particularly interesting subject for the study of oncogenic
alterations.
Clonally chromosomal aberrations are characteristics
of tumor cells and have been found in major tumor types.
Many such aberrations are established as prognostic and
predictive biomarkers including lung cancers.16 In NSCLC,
such events include amplification of EGFR17,25,26 and Kras
gene.14,15,33 In this report, we provide direct in situ evidence
that Kras ICN might somehow correlate with prognosis of
NSCLC.
The Ras/Raf pathway links the receptors for growth
factors with their downstream effects on gene transcrip-
tion, cellular proliferation, and survival. Although some
overlap with Kras-activating mutations occurred, our find-
ings indicated that Kras ICN itself is exited in some
population of NSCLC. Pulciani et al.5 reported that trans-
duction of a cell line with multiple copies of a wild-type
Ras protooncogene was sufficient to induce malignant trans-
formation in the absence of activating mutations. The author
analyzed 35 lung carcinomas for Ras gene amplification
using Southern blotting and reported a single case in which
Kras amplification was believed to have occurred.
FISH analysis may allow for assessment of the pres-
ence and pattern of amplification of a specific gene in indi-
vidual tumor cells. Thus, we were able to directly observe
Kras amplification and to distinguish low-level copy number
gains from high-level gains.27 FISH also allowed us to detect
amplification even when present in a subgroup of cells or
multifocally. Our observations suggest that in some tumors,
most cells contain many copies of Kras, whereas other
tumors consist of a few cells containing many copies of Kras
in the midst of a majority of cells containing low-level
amplification. The latter pattern raises the possibility that
accumulation of Kras in NSCLC could occur in a stepwise
manner, beginning with low-level copy number gains and
progressing through stages in which some cells continue to
accumulate Kras copies. This process of progressive Kras
accumulation has been observed during tumor progression in
a murine model.34 More recently, Singh et al.35 divided Kras
mutant population into two groups, Kras-dependent and
Kras-independent group. These might be explanation for our
results: a part of Kras mutant patients had poor prognosis
with increased Kras copy number.
In summary, Kras mutation was significantly associ-
ated with worse clinical outcome in patients with NSCLC,
but increased Kras gene copy number itself was not signifi-
cantly associated. In the respect of this result, the populations
with Kras mutation may be different from the populations
with increased Kras copy number, and the effect of increased
Kras copy number to prognosis may be different from that
of Kras mutation. Nevertheless, for our analysis using FISH,
Kras polysomy or amplification may still be a predictor of
lung cancers. In most studies, analysis of Kras copy number
has been performed by FISH14 or qPCR.15 FISH analysis was
relatively expensive and usually performed for one or few
sliced sections. Standardization of copy number analysis
should be required to evaluate the copy number accurately. In
our analysis, only one case had FISH amplification or high
polysomy. This is why we included six polysomy cases as
ICN, and using qPCR, more than 3 was determined as ICN.
The determination might affect well correlation with progno-
sis in our study. Actually, Takano et al.23 determined 3 as
increased EGFR copy number and Okuda et al.24 determined
3 as increased MET copy number. Thus, ICN of Kras in
NSCLC is moderate.
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